-
Dr. Zefei Jiang：Neoadjuvant-Adjuvant Pertuzumab in HER2-Positive Early Breast Cancer: Final Analysis of the Randomized Phase III PEONY Trial
Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital, along with his colleagues, published the groundbreaking article titled “Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial” in Nature Communications on March 9, 2024. This pivotal research examines the long-term efficacy and safety of…
-
Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation 2
At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Professor Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating…
-
BOC/BOA 2024 | Professor Shaohua Zhang: Treatment Strategies for Breast Cancer Patients Post-CDK4/6 Inhibitor Therapy
The results of studies such as postMONARCH and Young-PEARL presented at the 2024 ASCO Annual Meeting have sparked a new round of discussions on treatment strategies for patients with HR+/HER2- advanced breast cancer. To gain deeper insights into the significance of these studies and their implications for clinical practice, Professor Shaohua Zhang from The Fifth…
-
Professor Jianyun Nie: Discussing Consensus and Controversies in Breast Cancer Diagnosis and Treatment in the South of Colorful Clouds
The 8th Yunling Breast Cancer Summit Forum, hosted by the Yunnan Anti-Cancer Association and the China Medical Education Association and organized by Peking University Cancer Hospital Yunnan Hospital/Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center, Yunnan Breast Cancer Clinical Research Center, Yunnan Anti-Cancer Association Breast Cancer Professional Committee, Yunnan Medical Association…
-
Professor Guojun Zhang: Towering Yunling Mountains, Gathering of Renowned Experts, and Highlighting the New Heights of Breast Cancer Diagnosis
From July 12th to 14th, the 2024 CACA Integrated Breast Cancer Conference and The 8th Yunling Breast Cancer Summit Forum were held in Kunming, Yunnan. “Oncology Frontier” invited Professor Guojun Zhang, the chairman of both conferences and the president of Yunnan Cancer Hospital, to introduce the conference highlights, the hot directions of translational medicine research…
-
BOC/BOA 2024 | Professor Meng Wu: Major Advances in Lymphoma Treatment Boost Precision Medicine Development
From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. This conference focused on the “2023 Annual Progress in Clinical Oncology in China” selected by CSCO, aiming to deeply analyze the latest research achievements in the…
-
Expert Interview | Professor Victor Navarro: Management and Challenges of Drug-Induced Liver Injury in Oncology
In the journey of cancer treatment, drug-induced liver injury is a significant issue that cannot be overlooked. The “8th International Forum on Drug-Induced Liver Injury,” held on May 25, 2024, focused on the management of drug-induced liver injury caused by anticancer drugs, inviting numerous renowned experts and scholars from around the world for rich academic…
-
Clinical Characteristics and Treatment Strategies for Immune Checkpoint Inhibitor-Induced Liver Injury
Recently, the “8th International Forum on Drug-Induced Liver Injury and the 9th National Conference on Drug-Induced Liver Injury” along withthe release of the 2024 primary care version of “Chinese Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury” was held in the beautiful city of Xiamen. The theme of this conference focused on the…
Connecting Medical Expertise through Media